Medical Biotechnology MCQs (Set-4)

Difficulty: Hard

For equal-efficiency qPCR assays, sample X crosses threshold two cycles before sample Y. Approximately how much more starting target is in X?

A about twice as little
B about sixteen times less
C about four times as much
D the same amount

In 1,000 people, disease prevalence is 1%; a test has 99% sensitivity and 95% specificity. Its positive predictive value is closest to

A 95%
B 50%
C 99%
D 17%

A sandwich ELISA gives a weak signal even though target antigen is present. The capture and detection antibodies bind overlapping sites. What is a likely effect?

A the capture antibody turns into a reporter gene
B the test becomes a Western blot
C the assay will amplify the antigen DNA
D the detection antibody may be blocked from binding

A CAR recognizes a surface antigen on a tumor cell. How does this recognition differ from a conventional T-cell receptor?

A a CAR is an antibody secreted into plasma
B a CAR can bind an intact surface target without peptide presentation by MHC
C a CAR binds only DNA in the nucleus
D a T-cell receptor never recognizes peptides

A genome-editing therapy shows the intended edit in a target gene. Which evaluation is still needed?

A assume every edit is safe because the target was corrected
B measure only the target protein color
C assess unintended edits and relevant cell function using suitable methods
D skip genomic quality checks after editing

A cell therapy uses a patient’s cells collected, modified, and returned. What is a central advantage of this approach?

A the product can be tailored to that patient’s cells
B it guarantees lifelong benefit
C it removes all immune reactions
D it eliminates every manufacturing risk

An mRNA vaccine’s active instruction is translated in the cytoplasm. Which component supplies the encoded antigen information?

A the mRNA sequence
B the lipid nanoparticle alone
C the patient’s antibody genes
D the syringe needle

A molecular test has excellent analytical performance in a lab but fails in a new clinic because samples are poorly collected. What is the main lesson?

A sample collection cannot affect results
B analytical sensitivity guarantees clinical utility
C pre-analytic handling is part of overall test performance
D the assay should be judged only by its primer sequence

A medical test detects a biomarker associated with disease but not the cause itself. What wording is appropriate?

A the result establishes an inherited mutation
B the test replaces all clinical evaluation
C the result supports assessment but is not alone a definitive diagnosis
D the biomarker proves causation

A patient has a germline variant and a tumor-specific variant in separate samples. Which approach helps distinguish them?

A measure cell viability
B test only the tumor and assume inheritance
C compare tumor DNA with matched normal DNA
D use antibody ELISA for both sequences

A therapy’s effect depends on a patient’s tumor antigen expression. Which test can help assess the target protein in tissue?

A PCR of an unrelated housekeeping gene only
B immunohistochemistry with a validated antibody
C a semen motility test
D a plant tissue culture assay

A laboratory wants to confirm a specific protein’s presence and apparent molecular size after separation. Which method fits?

A DNA microarray
B ELISA for antibodies only
C Western blot
D RT-qPCR

A point-of-care biosensor must convert analyte binding into an electronic readout. Which component performs the conversion?

A transducer
B capture antigen
C culture flask
D PCR primer

A clinical sequencing result has low read depth at a variant site. What is the concern?

A the sample contains no chromosomes
B the variant is automatically pathogenic
C the call may be less reliable and may need confirmation
D the result proves the patient is healthy

A companion diagnostic is developed alongside a targeted therapy. Its purpose is to

A produce the drug in a fermenter
B make every patient respond identically
C replace the therapy’s quality testing
D identify patients or samples with a biomarker relevant to treatment

A cell product is contaminated with endotoxin from bacterial material. Which quality issue is present?

A an antibody titer
B a beneficial potency marker
C a genetic variant in the patient
D a safety impurity requiring control

An assay yields different results on repeated runs of the same reference sample. What should be checked first?

A precision, calibration, reagents, and operator or instrument variation
B the patient’s family history only
C the gene’s evolutionary origin
D whether the sample was transgenic

A clinical team uses a molecular test result to guide care. What is needed beyond analytical accuracy?

A clinical validation and evidence that the result is useful for the intended decision
B an unrelated animal model
C a larger sample label
D a brighter fluorescent dye only

A molecular diagnostic test is designed to detect one known mutation. Which probe or primer design is most important?

A a broad antibody against all proteins
B sequence complementarity to the variant and nearby target region
C an enzyme that digests every DNA molecule
D an unrelated promoter

A biopharmaceutical product is made in living cells and shows batch-to-batch variation. What is an important response?

A validate process controls and characterize product quality
B skip purification testing
C assume all batches are identical because the DNA is identical
D measure only the culture color

A patient has a disease-associated protein in plasma. Which approach can quantify that protein using an antigen-specific antibody and a standard curve?

A karyotyping
B ELISA
C DNA microarray
D PCR

A sample is tested for HIV antibodies using an antigen-coated plate and a labeled anti-human immunoglobulin. This is

A flow sorting
B indirect ELISA
C Western blot
D RT-PCR

A vaccine uses an mRNA instruction rather than a purified antigen. What happens after delivery?

A the mRNA becomes a chromosome in every cell
B the mRNA directly edits the immune-cell genome
C the vaccine contains a complete infectious pathogen
D some cells translate the mRNA into antigen

A gene-therapy study targets muscle cells and excludes reproductive cells. Which concern is reduced by this design?

A need for vector testing
B passing the modification to future generations
C variation in gene expression
D immune response in the treated person

A diagnostic assay is highly sensitive but has limited specificity. What is a likely consequence?

A more false-negative results among every infected person
B guaranteed detection of the cause
C no positives in the patient group
D more false-positive results among people without the target condition